Champignon Brands announces changes to strengthen its corporate governance, management
The company says its plans include recruiting a new CFO, chief general counsel, and senior VP of communications
Sector
Health
1063 stories · page 46 of 54
Emyria teams up with Mind Medicine Australia to develop national care program and data registry for psychedelic-assisted therapies
It will leverage on Emyria’s experience with unregistered medicines for patients with unmet needs across its national network of clinics – Emerald Clinics
Binovi Technologies appoints renowned educator Susan Barry to its Scientific Advisory Board
The company says Dr. Barry's work in the neurological examination of vision will be valuable in its pursuit of further testing and treatment options for students and patients
Thoughtful Brands achieves vertical integration with American CBD Extraction Corp acquisition
The company has acquired an abundance of hemp biomass along with a 41,000-square-foot facility that can process over 1,200 pounds of hemp per day
Binovi Technologies to raise up to C$2M to help advance neuro-visual technology
Binovi is developing neuro-visual technology to test, analyze, track and report individual cognitive performance
MindMed wraps up Phase 1 LSD study in partnership with Swiss lab; prepares for Phase 2 of 'Project Lucy'
The Phase 1 study measured subjective patient responses starting at microdoses up to experiential doses
Tetra Bio-Pharma completes divestiture of subsidiary Lumiera Health to Mondias Natural Products
The purchase price of C$1.3 million will be satisfied by the issuance of 16,250,000 Mondias shares at C$0.08 each
Binovi welcomes Candian Olympic gold medalist Jennifer Botterill as a brand ambassador, performance advisory board member
Botterill will promote resources within the Binovi product platform that are advantageous to sports performance users, the company said
Empower Clinics announces potential acquisition of Momentum Health, expanding its footprint into Canada
The firm has struck a non-binding deal to buy, via cash and shares, Lawrence Park Health and Wellness Clinic Inc, 1100900 Canada Inc dba Atkinson, and Momentum Health Inc, collectively called Momentum Health
Binovi Technologies brings in C$1.7M as it closes private placing
The tech group issued over 13.3 million units at C$0.1275 a throw. Each unit consisted of one company share and one share purchase warrant
Binovi Technologies raising C$1.7 million to fund K-12 education platform, Vima Strobe integration
The funds raised will go towards expanding the group's K-12 education platform as well as the integration of the Vima Strobe technology
Champignon Brands CEO Dr Roger McIntyre elected chairman of the board
Dr McIntyre is a professor of psychiatry and pharmacology at the University of Toronto and heads the Mood Disorders Unit at the University Health Network in Toronto
Mind Medicine to commit $5M to launch and develop clinical training program in field of psychedelic therapies and medicine
The biotech firm, which has filed to uplist on the Nasdaq exchange, said the program will take place at NYU Langone Health
Sensyne Health placing faith in its growing patient database
“Looking ahead, the group is well placed to accelerate its commercialisation plans through the three partnerships it struck within its discovery science division and the launch of its innovative app portfolio in the US from its software pro
Binovi Technologies congratulates Dallas Stars on NHL Western Conference Championship
The ice hockey team have added Binovi’s vision training to their programs to improve the vision and overall performance of each player
genedrive testing kit verified to work with Beckman Coulter extraction process
Initial testing took place using Beckman Coulter Life Sciences' chemistry on respiratory swabs in conjunction with gendrive’s 96 SARS-CoV-2 equipment
MindMed announces R&D collaboration with Liechti Lab in Switzerland on psilocybin
The pair will seek to better understand and compare the altered states of consciousness induced by psilocybin and LSD
Tiziana Life Sciences: HC Wainwright sees “meaningful upside” to price target if foralumab COVID-19 trial is a success
In its latest research, the US broker rates the shares a 'buy' and values them at U$11 each
Algernon Pharmaceuticals gets green light to continue its Phase 2b/3 coronavirus study from Data and Safety Monitoring Board
The drug repurposing firm said the DSMB had unanimously approved the continuation of the study
Humanigen and Lonza reveal collaboration to expand manufacturing COVID-19 therapeutic candidate lenzilumab
The collaboration ramps up lenzilumab manufacturing capacity ahead of anticipated Emergency Use Authorization for the drug in 2020